Induction protocols for pediatric renal transplant recipients commonly utilize polyclonal or monoclonal agents in sequence with additional immunosuppression. Polyclonal agents Minnesota antilymphoblast globulin (MALG), anti-thymocyte globulin (ATGAM) effect both T and B cells while monoclonal agents (OKT3) are T-cell specific. Flow cytometric analysis of T-cell subsets has become the marker of adequacy of immunosuppression during OKT3 therapy, yet to date no marker exists to measure the adequacy of immunosuppression with polyclonal agents. At the University of Michigan, flow cytometric analysis in pediatric renal transplant recipients undergoing polyclonal induction reveals that CD3, CD4, and CD8 suppression initially occurs. As opposed to OKT3, a rebound of CD3 cells occurs despite daily use of a polyclonal agent in sequence with additional immunosuppressives. During these analyses, a single kidney was lost which flow cytometry failed to predict. No significant difference in flow cytometric patterns occurred when comparing ATGAM to MALG induction. Flow cytometry utilized during polyclonal induction in pediatric renal transplant recipients revealed a variety of T-cell suppression patterns but failed to demonstrate persistence of suppression. Despite this lack of suppression as indicated by flow cytometry, a 97% 1 year allograft survival rate exists in the pediatric transplant program at the University of Michigan Medical Center. Therefore, the role of flow cytometry during polyclonal induction has yet to be well defined. o 1995 Wiley-Liss, inc.Key terms: T-cell subsets, pediatric renal transplantation, immunosuppression CD3 suppression, as measured by flow cytometry, is the marker for the adequacy of therapy during the use of monoclonal antibody OKT3 (Ortho, Raritan, NJ) ( 1 ). CD4, as well as CD8, suppression does occur during the early stages of OKT3 administration, yet rebounds relatively early in the course. Polyclonal agents utilized in North America such as Minnesota antilymphoblast globulin (MALG) or ATGAM (Upjohn, Kalamazoo, MI) are other agents utilized in organ transplantation. A recent study at the University of Michigan revealed that CD3, CD4, as well as CD8 suppression occurs early during induction therapy with MALG in a pediatric renal transplant recipient. A tendency toward normalization of these T-cell subsets occurs by 4 or 5 d despite a 10 d course of MALG administration (2). Due to the unavailability of MALG, a transition from MALG to ATGAM induction has occurred both nationally as well as at the University of Michigan. N o pediatric data exist, to date, comparing the efficacy of MALG to ATGAM. Therefore, previous T-cell suppression of MALG cannot be extrapolated to ATGAM.Over the last 2.5 years we have evaluated T-cell subsets during induction therapy as measured by flow cytometry. Induction therapy in all cases has included the use of a polyclonal agent. Herein is a report of the use of flow 6 1995 Wiley-Liss, Inc cytometry during polyclonal induction in the pediatric renal recipient. Its ef...